Literature DB >> 10761708

Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families.

M Yoshida1, S Ashida, K Kondo, K Kobayashi, H Kanno, N Shinohara, N Shitara, T Kishida, S Kawakami, M Baba, I Yamamoto, M Hosaka, T Shuin, M Yao.   

Abstract

We have previously reported on the analysis of germ-line mutations in Japanese von Hippel-Lindau disease (VHL) patients and found mutations in 26 families. We have now extended these studies to include an additional 41 VHL families. Germ-line mutation of the VHL gene was screened by DNA-SSCP, direct sequencing, and Southern blot analysis. To summarize all of the data we have studied in this and our previous report, germ-line mutations have been detected in 55 of 77 (73%) (type 1: 41/62 (66%) and type 2: 14/15 (93%)) families. We found similarities in the nature of germ-line mutations including mutational incidence, location, and DNA substitution patterns between Japanese and Western VHL. These similarities may reflect the predominance of endogenous mutational processes. We also found several interesting characteristics in Japanese VHL. Twenty of 41 (49%) intragenic mutations were unique and not reported in the Western VHL. Four mutations (Arg113Stop, Gln132Stop, Leu158Val, and Cys162Tyr) previously characterized as type 1 mutations were identified in the type 2 (with pheochromocytoma) Japanese families. Genotype-phenotype correlation study suggested non-missense mutations predicted to result in the loss of VHL function were associated with the occurrence of renal cell carcinoma, as in sporadic tumors. Our data add to the diversity of VHL germ-line mutations and provide a better understanding of VHL disease in terms of both clinical management and molecular pathogenesis.

Entities:  

Mesh:

Year:  2000        PMID: 10761708      PMCID: PMC5926327          DOI: 10.1111/j.1349-7006.2000.tb00933.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  VHL gene mutation and clear-cell renal carcinomas.

Authors:  A G Knudson
Journal:  Cancer J Sci Am       Date:  1995 Sep-Oct

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes.

Authors:  H Okuda; S Hirai; Y Takaki; M Kamada; M Baba; N Sakai; T Kishida; S Kaneko; M Yao; S Ohno; T Shuin
Journal:  Biochem Biophys Res Commun       Date:  1999-09-24       Impact factor: 3.575

5.  Third International Meeting on von Hippel-Lindau disease.

Authors:  B Zbar; W Kaelin; E Maher; S Richard
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

6.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

7.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Authors:  C E Stebbins; W G Kaelin; N P Pavletich
Journal:  Science       Date:  1999-04-16       Impact factor: 47.728

8.  Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Clinical Research Group for VHL in Japan.

Authors: 
Journal:  Hum Mol Genet       Date:  1995-12       Impact factor: 6.150

9.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

Authors:  A Schoenfeld; E J Davidowitz; R D Burk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Molecular genetic diagnosis of von Hippel-Lindau disease: analysis of five Japanese families.

Authors:  H Kanno; T Shuin; K Kondo; S Ito; M Hosaka; S Torigoe; S Fujii; Y Tanaka; I Yamamoto; I Kim; M Yao
Journal:  Jpn J Cancer Res       Date:  1996-05
View more
  14 in total

1.  Hemangioblastomatosis of the central nervous system without von Hippel-Lindau disease: a case report.

Authors:  Masayasu Kato; Naoyuki Ohe; Ayumi Okumura; Jun Shinoda; Asuka Nomura; Taro Shuin; Noboru Sakai
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

2.  Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.

Authors:  Ying Wang; Jingyun Yang; Guhong Du; Dexuan Ma; Liangfu Zhou
Journal:  Mol Carcinog       Date:  2017-06-30       Impact factor: 4.784

3.  Total pancreatectomy for multiple neuroendocrine tumors of the pancreas in a patient with von Hippel-Lindau disease.

Authors:  Hiromichi Maeda; Isao Nishimori; Takehiro Okabayashi; Takuhiro Kohsaki; Taro Shuin; Michiya Kobayashi; Saburo Onishi; Kazuhiro Hanazaki
Journal:  Clin J Gastroenterol       Date:  2009-03-19

4.  A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?

Authors:  Fatemeh Azimi; Ali Aghajani; Golnaz Khakpour; Samira Chaibakhsh
Journal:  Mol Genet Genomics       Date:  2022-08-25       Impact factor: 2.980

5.  Germline mutations in the von Hippel-Lindau disease (VHL) gene in mainland Chinese families.

Authors:  Jin Zhang; Yiran Huang; Jiahua Pan; Dongming Liu; Lixin Zhou; Wei Xue; Qi Chen; Baijun Dong; Hanqing Xuan
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-30       Impact factor: 4.553

6.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

7.  Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease.

Authors:  Masatsugu Okuyama; Yasuhiro Fujiwara; Tsuyoshi Hayakawa; Masatsugu Shiba; Toshio Watanabe; Kazunari Tominaga; Akihiro Tamori; Nobuhide Oshitani; Kazuhide Higuchi; Takayuki Matsumoto; Kenji Nakamura; Kenichi Wakasa; Kazuhiro Hirohashi; Shingo Ashida; Taro Shuin; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

8.  A mutation at IVS1 + 5 of the von Hippel-Lindau gene resulting in intron retention in transcripts is not pathogenic in a patient with a tongue cancer?: case report.

Authors:  Takeshi Asakawa; Mariko Esumi; Sohei Endo; Akinori Kida; Minoru Ikeda
Journal:  BMC Med Genet       Date:  2012-03-31       Impact factor: 2.103

9.  Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis.

Authors:  Hyun-Jung Cho; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

10.  Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease.

Authors:  Gautham Arunachal; Divya Pachat; C George Priya Doss; Sumita Danda; Rekha Pai; Andrew Ebenazer
Journal:  Genet Res Int       Date:  2016-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.